Petosemtamab Clinical Trials (2026): 3 Studies for Head and Neck Squamous Cell Carcinoma & Lung Cancer - Non Small Cell Non-Squamous
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 Petosemtamab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Head and Neck Squamous Cell Carcinoma & Lung Cancer - Non Small Cell Non-Squamous) and 1,321 total planned enrollment. 2 Phase 3 Petosemtamab trials and 1 Phase 2 are listed. 1 Petosemtamab clinical trial is actively recruiting at 36 U.S. sites across 20 states. Most recent activity: NCT07353957 (Feb 2031).
Where to Participate: All Petosemtamab Trial Sites in the U.S. (36 sites across 20 states)
Every actively recruiting Petosemtamabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Site 164 | Mobile36607 | NCT06525220 | Map |
| CA | Site 36 | La Jolla92037 | NCT06525220 | Map |
| CA | Site 27 | Los Angeles90033 | NCT06525220 | Map |
| CA | Site 16 | Palo Alto94304 | NCT06525220 | Map |
| DE | Site 19 | Newark19713 | NCT06525220 | Map |
| DC | Site 108 | Washington D.C.20010 | NCT06525220 | Map |
| FL | Site 14 | Fort Myers33901 | NCT06525220 | Map |
| FL | Site 8 | Orlando32827 | NCT06525220 | Map |
| FL | Site 21 | St. Petersburg33705 | NCT06525220 | Map |
| FL | Site 20 | West Palm Beach33401 | NCT06525220 | Map |
| GA | Site 171 | Atlanta30322 | NCT06525220 | Map |
| IL | Site 197 | Chicago60611 | NCT06525220 | Map |
| IL | Site 50 | Chicago60637 | NCT06525220 | Map |
| KY | Site 2 | Louisville40202 | NCT06525220 | Map |
| LA | Site 162 | Baton Rouge70809 | NCT06525220 | Map |
| MN | Site 155 | Minneapolis55417 | NCT06525220 | Map |
| MO | Site 168 | St Louis63108 | NCT06525220 | Map |
| NJ | Site 94 | Hackensack07601 | NCT06525220 | Map |
| NM | Site 6 | Albuquerque87131 | NCT06525220 | Map |
| NC | Site 113 | Durham27710 | NCT06525220 | Map |
| NC | Site 118 | Winston-Salem27157 | NCT06525220 | Map |
| OH | Site 191 | Cleveland44195 | NCT06525220 | Map |
| PA | Site 153 | Philadelphia19107 | NCT06525220 | Map |
| PA | Site 154 | Philadelphia19114 | NCT06525220 | Map |
| PA | Site 43 | Philadelphia19104 | NCT06525220 | Map |
| TN | Site 89 | Chattanooga37404 | NCT06525220 | Map |
| TN | Site 115 | Memphis38103 | NCT06525220 | Map |
| TN | Site 88 | Nashville37203 | NCT06525220 | Map |
| TX | Site 22 | Austin78745 | NCT06525220 | Map |
| TX | Site 1 | Houston77030 | NCT06525220 | Map |
| TX | Site 18 | Plano75075 | NCT06525220 | Map |
| TX | Site 17 | Sugar Land77479 | NCT06525220 | Map |
| TX | Site 15 | Tyler75702 | NCT06525220 | Map |
| UT | Site 10 | Salt Lake City84112 | NCT06525220 | Map |
| VA | Site 12 | Blacksburg24060 | NCT06525220 | Map |
| VA | Site 23 | Norfolk23502 | NCT06525220 | Map |
Petosemtamab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | withdrawn | Total |
|---|---|---|---|---|
| P2 | 1 | 1 | ||
| P3 | 1 | 1 | 2 |
Recruiting Petosemtamab clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | P3 | Head and Neck Squamous Cell Carcinoma | 700 | Sep 2024 |
Petosemtamab clinical trials by indication
Head and Neck Squamous Cell Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06525220 | — | P3 | recruiting | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) |
| NCT06496178 | — | P3 | active not recruiting | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) |
Lung Cancer - Non Small Cell Squamous (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07353957 | — | P2 | withdrawn | Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer |
Terminated and withdrawn Petosemtamab trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT07353957withdrawnStudy to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
All Petosemtamab trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07353957 | Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer | P2 | withdrawn | 0 | Merus B.V. | Mar 2026 | |
| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | P3 | recruiting | 700 | Merus B.V. | Sep 2024 | |
| NCT06496178 | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) | P3 | active not recruiting | 621 | Merus B.V. | Jun 2024 |
Petosemtamab clinical trials: frequently asked questions
- How many Petosemtamab clinical trials are there?
- 3 Petosemtamab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are Petosemtamab clinical trials recruiting in 2026?
- Yes — 1 Petosemtamab trial is actively recruiting in 2026, with 36 U.S. sites across 20 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Petosemtamab being studied for?
- Petosemtamab is being studied for Head and Neck Squamous Cell Carcinoma, Lung Cancer - Non Small Cell Non-Squamous, Lung Cancer - Non Small Cell Squamous. The trials are grouped by indication on this page.
- What phase is Petosemtamab in?
- Petosemtamab clinical trials span 2 Phase 3, 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Petosemtamab clinical trials?
- The lead sponsor across the most Petosemtamab trials is Merus B.V.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Petosemtamabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: